Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Cerebrospinal fluid and serum Interleukin-6 and its receptors levels in relapsing-remitting multiple sclerosis patients (CROSBI ID 484728)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Horvat, Gordana ; Vladić, Anton ; Zadro, Ivana ; Vukadin, Stipe ; Čulo, Filip Cerebrospinal fluid and serum Interleukin-6 and its receptors levels in relapsing-remitting multiple sclerosis patients // European Journal of Neurology. Oxford: Wiley-Blackwell, 2002. str. 135-135-x

Podaci o odgovornosti

Horvat, Gordana ; Vladić, Anton ; Zadro, Ivana ; Vukadin, Stipe ; Čulo, Filip

engleski

Cerebrospinal fluid and serum Interleukin-6 and its receptors levels in relapsing-remitting multiple sclerosis patients

Introduction: Inteleukin-6 (IL-6) has recently been implicated in the pathogenesis of multiple sclerosis, as it was found localized in MS lesions. The functional receptor for IL-6 is a complex of signal transducing subunit glycoprotein 130 (sgp130) and the ligand binding subunit gp80 (sIL-6R). They interact to mediate intracellular signalling. The aim of this study was to measure IL-6 and its soluble receptors (sIL-6R and sgp130) in the cerebrospinal fluid (CSF) and serum from relapsing-remitting MS patients (RRMS). Patients and methods: We analysed CSF and serum samples of 21 RRMS patients during acute exacerbation of the disease, and 19 patients with noninflammatory neurological diseases (NIND), as controls. IL-6, sIL-6R and sgp130 levels were measured using enzymeimmuno test (ELISA). One-way ANOVA was applied for statistical analysis of the data. Results: Our preliminary results (mean&plusmn ; S.D. in pg/mL) showed statistically different serum IL-6 level in RRMS (27.79&plusmn ; 61.33) and NIND (106.04&plusmn ; 125.93) patients. However, there was no statistical difference between CSF IL-6 level in RRMS (2.90&plusmn ; 2.68) and NIND (2.97&plusmn ; 2.59) patients. Serum sIL-6R level was not statistically different between RRMS (25 795.55&plusmn ; 8511.27) and NIND (21840.12&plusmn ; 6379.43) patients, but CSF level were statistically different between RRMS (630.26&plusmn ; 522.19) and NIND (159.84&plusmn ; 273.41) group. Serum sgp130 levels were statistically different in RRMS (333750&plusmn ; 88070) and NIND (415590&plusmn ; 124160) patients. The CSF sgp130 level between RRMS (46710&plusmn ; 26280) and NIND (54250&plusmn ; 22560) group was not statistically different. Conclusion: Our preliminary results suggest that IL-6 and its soluble receptors (sIL-6R and sgp130) regulation may be altered in RRMS during acute exacerbation of the disease.

Il-6; RRMS; CSF; serum

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

135-135-x.

2002.

objavljeno

Podaci o matičnoj publikaciji

European Journal of Neurology

Oxford: Wiley-Blackwell

Podaci o skupu

6th Congress of European Federation of Neurological Societies

poster

26.10.2002-29.10.2002

Beč, Austrija

Povezanost rada

Farmacija